The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Alternatively spliced androgen receptor variants
Open accessAbstract
Alternative splicing is an important mechanism for increasing functional diversity from a limited set of genes. Deregulation of this process is common in diverse pathologic conditions. The androgen receptor (AR) is a steroid receptor transcription factor with functions critical for normal male development as well as the growth and survival of normal and cancerous prostate tissue. Studies of AR function in androgen insensitivity syndrome (AIS) and prostate cancer (PCa) have demonstrated loss-of-function AR alterations in AIS and gain-of-function AR alterations in PCa. Over the past two decades, AR gene alterations have been identified in various individuals with AIS, which disrupt normal AR splicing patterns and yield dysfunctional AR protein variants. Recently, altered AR splicing patterns have been identified as a mechanism of PCa progression and resistance to androgen depletion therapy. Several studies have described the synthesis of alternatively spliced transcripts encoding truncated AR isoforms that lack the ligand-binding domain, which is the ultimate target of androgen depletion. Many of these truncated AR isoforms function as constitutively active, ligand-independent transcription factors that can support androgen-independent expression of AR target genes, as well as the androgen-independent growth of PCa cells. In this review, we will summarize the various alternatively spliced AR variants that have been discovered, with a focus on their role and origin in the pathologic conditions of AIS and PCa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The American Journal of Human Genetics
S., J. (1950) · Population (French Edition) · doi:10.2307/1523704 · Cited by 5,028
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“This drug blocks intra-tumor conversion of progesterone and adrenal androgens to DHT (Attard et al. 2009) and a recent phase III trial demonstrated an overall survival benefit for abiraterone in men with metastatic CRPCa (de Bono et al. 2011).”
BackgroundDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Steroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones*
Pratt, W. B., & Toft, D. O. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.3.0303 · Cited by 1,791
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M.-E., Efstathiou, E., Rathkopf, D., Shelkey, J., Yu, E. Y., Alumkal, J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Self-citationHeemers, H. V., & Tindall, D. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0019 · Cited by 753
Self-citationSun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012443107 · Cited by 639
Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor
Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004571200 · Cited by 608
Sack, J. S., Kish, K. F., Wang, C., Attar, R. M., Kiefer, S. E., An, Y., Wu, G. Y., Scheffler, J. E., Salvati, M. E., Krystek, S. R., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081565498 · Cited by 491
Lubahn, D. B., Brown, T. R., Simental, J. A., Higgs, H. N., Migeon, C. J., Wilson, E. M., & French, F. S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.23.9534 · Cited by 452
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
Pienta, K. J., & Bradley, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0067 · Cited by 430
Structural basis of androgen receptor binding to selective androgen response elements
Shaffer, P. L., Jivan, A., Dollins, D. E., Claessens, F., & Gewirth, D. T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401123101 · Cited by 400
He, B., Kemppainen, J. A., Voegel, J. J., Gronemeyer, H., & Wilson, E. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37219 · Cited by 372
Nuclear Receptor Structure: Implications for Function
Bain, D. L., Heneghan, A. F., Connaghan-Jones, K. D., & Miura, M. T. (2007) · Annual Review of Physiology · doi:10.1146/annurev.physiol.69.031905.160308 · Cited by 366
Molecular basis of androgen insensitivity
Brinkmann, A. O. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00466-x · Cited by 348
Molecular regulation of androgen action in prostate cancer.
Dehm, S. M., & Tindall, D. J. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20794 · Cited by 336
Self-citationChen, Y., Clegg, N. J., & Scher, H. I. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70229-3 · Cited by 324
Zhou, Z. X., Sar, M., Simental, J. A., Lane, M. V., & Wilson, E. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36806-0 · Cited by 312
The androgen receptor gene mutations database (ARDB): 2004 update
Gottlieb, B., Beitel, L. K., Wu, J. H., & Trifiro, M. (2004) · Human Mutation · doi:10.1002/humu.20044 · Cited by 311
Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer
Knudsen, K. E., & Scher, H. I. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2660 · Cited by 307
He, B., Gampe, R. T., Kole, A. J., Hnat, A. T., Stanley, T. B., An, G., Stewart, E. L., Kalman, R. I., Minges, J. T., & Wilson, E. M. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.09.036 · Cited by 295
Alen, P., Claessens, F., Verhoeven, G., Rombauts, W., & Peeters, B. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6085 · Cited by 268
Tepper, C. G., Boucher, D. L., Ryan, P. E., Ma, A., Xia, L. P., Lee, L., Pretlow, T. G., & Kung, H.-J. (2002) · PubMed · Cited by 265
Recognition and Accommodation at the Androgen Receptor Coactivator Binding Interface
Hur, E., Pfaff, S. J., Payne, E. S., Grøn, H., Buehrer, B. M., & Fletterick, R. J. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020274 · Cited by 234
Structural basis for the nuclear import of the human androgen receptor
Cutress, M. L., Whitaker, H. C., Mills, I. G., Stewart, M., & Neal, D. E. (2008) · Journal of Cell Science · doi:10.1242/jcs.022103 · Cited by 223
Hu, R., Isaacs, W. B., & Luo, J. (2011) · The Prostate · doi:10.1002/pros.21382 · Cited by 207
Li, Y., Alsagabi, M., Fan, D., Bova, G. S., Tewfik, A. H., & Dehm, S. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1998 · Cited by 199
Self-citationSmith, D. F., & Toft, D. O. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0089 · Cited by 173
Attard, G., Reid, A. H. M., Olmos, D., & de Bono, J. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4531 · Cited by 168
Estébanez-Perpiñá, E., Moore, J. M. R., Mar, E., Delgado-Rodrigues, E., Nguyen, P., Baxter, J. D., Buehrer, B. M., Webb, P., Fletterick, R. J., & Guy, R. K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m407046200 · Cited by 164
Watson, P. A., Ellwood-Yen, K., King, J. C., Wongvipat, J., LeBeau, M. M., & Sawyers, C. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-3441 · Cited by 159
Androgen receptor action in hormone‐dependent and recurrent prostate cancer
Agoulnik, I. U., & Weigel, N. L. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20811 · Cited by 144
Evidence for Calpain-Mediated Androgen Receptor Cleavage as a Mechanism for Androgen Independence
Libertini, S. J., Tepper, C. G., Rodriguez, V., Asmuth, D. M., Kung, H.-J., & Mudryj, M. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1072 · Cited by 129
Chamberlain, N. L., Whitacre, D. C., & Miesfeld, R. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.43.26772 · Cited by 127
Androgen receptor function is modulated by the tissue-specific AR45 variant
Ahrens‐Fath, I., Politz, O., Geserick, C., & Haendler, B. (2004) · FEBS Journal · doi:10.1111/j.1432-1033.2004.04395.x · Cited by 119
Interplay between two hormone-independent activation domains in the androgen receptor.
Callewaert, L., Van Tilborgh, N., & Claessens, F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2389 · Cited by 111
Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action
Ding, D., Xu, L., Menon, M., Reddy, G. P. V., & Barrack, E. R. (2004) · The Prostate · doi:10.1002/pros.20128 · Cited by 111
Ris‐Stalpers, C., Kuiper, G. G. J. M., Faber, P. W., Schweikert, H. U., van Rooij, H. C., Zegers, N. D., Hodgins, M. B., DEGENHART, H. J., Trapman, J., & Brinkmann, A. O. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.20.7866 · Cited by 110
Marcias, G., Erdmann, É., Lapouge, G., Siebert, C., Barthélémy, P., Duclos, B., Bergerat, J., Céraline, J., & Kurtz, J. (2009) · Human Mutation · doi:10.1002/humu.21138 · Cited by 105
Androgen axis in prostate cancer.
Culig, Z., & Bartsch, G. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20898 · Cited by 102
Effect of a short CAG (glutamine) repeat on human androgen receptor function
Ding, D., Xu, L., Menon, M., Reddy, G. P. V., & Barrack, E. R. (2003) · The Prostate · doi:10.1002/pros.10316 · Cited by 99
Dehm, S. M., Regan, K. M., Schmidt, L. J., & Tindall, D. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1267 · Cited by 84
Self-citationThe androgen receptor CAG repeat: a modifier of carcinogenesis?
Ferro, P., Catalano, M. G., Dell’Eva, R., Fortunati, N., & Pfeffer, U. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00104-1 · Cited by 73
Jagla, M., Fève, M., Kessler, P., Lapouge, G., Erdmann, É., Serra, S., Bergerat, J., & Céraline, J. (2007) · Endocrinology · doi:10.1210/en.2007-0446 · Cited by 73
Ris‐Stalpers, C., Verleun-Mooijman, M. C. T., de Blaeij, T. J., DEGENHART, H. J., Trapman, J., & Brinkmann, A. O. (1994) · PubMed Central · Cited by 51
Brüggenwirth, H. T., Boehmer, A. L. M., Ramnarain, S., Verleun-Mooijman, M. C. T., Satijn, D. P. E., Trapman, J., Grootegoed, J. A., & Brinkmann, A. O. (1997) · The American Journal of Human Genetics · doi:10.1086/301605 · Cited by 47
Chen, H., Libertini, S. J., Wang, Y., Kung, H., Ghosh, P., & Mudryj, M. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.049379 · Cited by 37
Hellwinkel, O., Holterhus, P., Struve, D., Marschke, C., Homburg, N., & Hiort, O. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7543 · Cited by 33
Hellwinkel, O., Bull, K., Holterhus, P., Homburg, N., Struve, D., & Hiort, O. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00157-5 · Cited by 29
Wu, Z.-Y., Chen, K., Haendler, B., McDonald, T. V., & Bian, J. (2008) · Endocrinology · doi:10.1210/en.2007-1802 · Cited by 27
Lim, J. T. S., Ghadessy, F. J., & Yong, E. (1997) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(97)00109-3 · Cited by 24
Sammarco, I., Grimaldi, P., Rossi, P., Cappa, M., Moretti, C., Frajese, G., & Geremia, R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.9.3256 · Cited by 12
Cited by
Karantanos, T., Corn, P. G., & Thompson, T. C. (2013) · Oncogene · doi:10.1038/onc.2013.206 · Cited by 866
RNA splicing factors as oncoproteins and tumour suppressors
Dvinge, H., Kim, E., Abdel-Wahab, O., & Bradley, R. K. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.51 · Cited by 687
Li, Y., Chan, S. C., Brand, L. J., Hwang, T. H., Silverstein, K. A. T., & Dehm, S. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3630 · Cited by 680
Self-citationMechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015) · PubMed · doi:10.3978/j.issn.2223-4683.2015.05.02 · Cited by 514
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 420
Metadata
- Authors
- Dehm, S. M., & Tindall, D. J.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2011-07-21
- Volume
- 18
- Issue
- 5
- Pages
- R183-R196
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2136344158
- Cited by
- 380
- References
- 57
- FWCI
- 25.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.